Dendritic Cells and the Promise of Antigen-specific Therapy in Rheumatoid Arthritis

Overview

Journal Arthritis Res Ther

Publisher Biomed Central

Specialty Rheumatology

Date 2013 Feb 5

PMID 23374912

Citations 22

Authors

Ranjeny Thomas

Affiliations

Soon will be listed here.

Abstract

Rheumatoid arthritis (RA) is a systemic inflammatory disease resulting from an autoimmune response to self-antigens, leading to inflammation of synovial tissue of joints and subsequent cartilage and bone erosion. Current disease-modifying anti-rheumatic drugs and biologic inhibitors of TNF, IL-6, T cells and B cells block inflammation nonspecifically, which may lead to adverse effects, including infection. They do not generally induce long-term drug-free remission or restoration of immune tolerance to self-antigens, and lifelong treatment is usual. The development of antigen-specific strategies in RA has so far been limited by insufficient knowledge of autoantigens, of the autoimmune pathogenesis of RA and of the mechanisms of immune tolerance in man. Effective tolerance-inducing antigen-specific immunotherapeutic strategies hold promise of greater specificity, of lower toxicity and of a longer-term solution for controlling or even preventing RA. This paper reviews current understanding of autoantigens and their relationship to immunopathogenesis of RA, and emerging therapeutics that aim to leverage normal tolerance mechanisms for implementation of antigen-specific therapy in RA.

Citing Articles

[Research progress on the role of dendritic cells in immune metabolism of rheumatoid arthritis].

Han G, Sun S, Wang Q, Kang P Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2024; 38(12):1537-1541.

PMID: 39694847 PMC: 11655367. DOI: 10.7507/1002-1892.202408002.

Therapy targeting antigen-specific T cells by a peptide-based tolerizing vaccine against autoimmune arthritis.

Urbonaviciute V, Romero-Castillo L, Xu B, Luo H, Schneider N, Weisse S Proc Natl Acad Sci U S A. 2023; 120(25):e2218668120.

PMID: 37307481 PMC: 10288627. DOI: 10.1073/pnas.2218668120.

The emerging role of regulatory cell-based therapy in autoimmune disease.

Ghobadinezhad F, Ebrahimi N, Mozaffari F, Moradi N, Beiranvand S, Pournazari M Front Immunol. 2023; 13:1075813.

PMID: 36591309 PMC: 9795194. DOI: 10.3389/fimmu.2022.1075813.

14-3-3ζ: A suppressor of inflammatory arthritis.

Kim J, Chun K, McGowan J, Zhang Y, Czernik P, Mell B Proc Natl Acad Sci U S A. 2021; 118(34).

PMID: 34408018 PMC: 8403930. DOI: 10.1073/pnas.2025257118.

The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions.

Shams S, Martinez J, Dawson J, Flores J, Gabriel M, Garcia G Front Pharmacol. 2021; 12:680043.

PMID: 34122106 PMC: 8194305. DOI: 10.3389/fphar.2021.680043.

References

Leeming D, Bay-Jensen A, Vassiliadis E, Larsen M, Henriksen K, Karsdal M . Post-translational modifications of the extracellular matrix are key events in cancer progression: opportunities for biochemical marker development. Biomarkers. 2011; 16(3):193-205. DOI: 10.3109/1354750X.2011.557440. View

Yoshimura S, Bondeson J, Brennan F, Foxwell B, Feldmann M . Role of NFkappaB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI. Eur J Immunol. 2001; 31(6):1883-93. DOI: 10.1002/1521-4141(200106)31:6<1883::aid-immu1883>3.0.co;2-v. View

Roncarolo M, Gregori S, Lucarelli B, Ciceri F, Bacchetta R . Clinical tolerance in allogeneic hematopoietic stem cell transplantation. Immunol Rev. 2011; 241(1):145-63. DOI: 10.1111/j.1600-065X.2011.01010.x. View

Correale J, Farez M, Gilmore W . Vaccines for multiple sclerosis: progress to date. CNS Drugs. 2008; 22(3):175-98. DOI: 10.2165/00023210-200822030-00001. View

Charbonnier L, Han W, Quentin J, Huizinga T, Zwerina J, Toes R . Adoptive transfer of IL-10-secreting CD4+CD49b+ regulatory T cells suppresses ongoing arthritis. J Autoimmun. 2009; 34(4):390-9. DOI: 10.1016/j.jaut.2009.10.003. View

Verstraeten A, Sileghem A, Dequeker J . OM-8980 and D-penicillamine in the treatment of rheumatoid arthritis. A 12-month double-blind randomized study. Scand J Rheumatol. 1990; 19(6):422-31. DOI: 10.3109/03009749009097631. View

Levings M, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo M . Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood. 2004; 105(3):1162-9. DOI: 10.1182/blood-2004-03-1211. View

Scher J, Ubeda C, Equinda M, Khanin R, Buischi Y, Viale A . Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum. 2012; 64(10):3083-94. PMC: 3428472. DOI: 10.1002/art.34539. View

Yoo S, You S, Yoon H, Kim D, Kim H, Lee K . A novel pathogenic role of the ER chaperone GRP78/BiP in rheumatoid arthritis. J Exp Med. 2012; 209(4):871-86. PMC: 3328363. DOI: 10.1084/jem.20111783. View

10.

Snir O, Rieck M, Gebe J, Yue B, Rawlings C, Nepom G . Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients. Arthritis Rheum. 2011; 63(10):2873-83. PMC: 3174345. DOI: 10.1002/art.30445. View

11.

Raychaudhuri S, Sandor C, Stahl E, Freudenberg J, Lee H, Jia X . Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012; 44(3):291-6. PMC: 3288335. DOI: 10.1038/ng.1076. View

12.

Thomas R, Davis L, Lipsky P . Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells. J Immunol. 1994; 152(5):2613-23. View

13.

Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, van Venrooij W . A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther. 2004; 6(4):R303-8. PMC: 464874. DOI: 10.1186/ar1187. View

14.

Moreland L, Morgan E, Adamson 3rd T, Fronek Z, Calabrese L, Cash J . T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides. Arthritis Rheum. 1998; 41(11):1919-29. DOI: 10.1002/1529-0131(199811)41:11<1919::AID-ART5>3.0.CO;2-1. View

15.

van der Helm-van Mil A, Verpoort K, le Cessie S, Huizinga T, de Vries R, Toes R . The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum. 2007; 56(2):425-32. DOI: 10.1002/art.22373. View

16.

Sun W, Nie H, Li N, Zang Y, Zhang D, Feng G . Skewed T-cell receptor BV14 and BV16 expression and shared CDR3 sequence and common sequence motifs in synovial T cells of rheumatoid arthritis. Genes Immun. 2005; 6(3):248-61. DOI: 10.1038/sj.gene.6364166. View

17.

Gregersen P, Silver J, Winchester R . The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987; 30(11):1205-13. DOI: 10.1002/art.1780301102. View

18.

Pettit A, MacDonald K, OSullivan B, Thomas R . Differentiated dendritic cells expressing nuclear RelB are predominantly located in rheumatoid synovial tissue perivascular mononuclear cell aggregates. Arthritis Rheum. 2000; 43(4):791-800. DOI: 10.1002/1529-0131(200004)43:4<791::AID-ANR9>3.0.CO;2-E. View

19.

Schambach F, Schupp M, Lazar M, Reiner S . Activation of retinoic acid receptor-alpha favours regulatory T cell induction at the expense of IL-17-secreting T helper cell differentiation. Eur J Immunol. 2007; 37(9):2396-9. DOI: 10.1002/eji.200737621. View

20.

Vanderlugt C, Miller S . Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002; 2(2):85-95. DOI: 10.1038/nri724. View